Majedie Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Majedie Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5.14M	Buy	+31,529	New	+$4.8M	0.42%	69

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Majedie Asset Management's ALNY Position: Q1 2022 in Review

Majedie Asset Management opened a new position in Alnylam Pharmaceuticals (ALNY) in Q1 2022: 31,529 shares worth $5.14M. The stake represents 0.42% of the portfolio and ranks #69 among its holdings.

443 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.

Majedie Asset Management held 31,529 shares of Alnylam Pharmaceuticals worth $5.14M as of Q1 2022.
Alnylam Pharmaceuticals was a new Majedie Asset Management position in Q1 2022.
Alnylam Pharmaceuticals made up 0.42% of Majedie Asset Management's portfolio in Q1 2022, its #69 holding.
443 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.

Based on Majedie Asset Management's 13F filing for Q1 2022, filed 16 May 2022.